Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03053193 · ClinicalTrials.gov registry record
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
A clinical trial of Breast Cancer, sponsored by Agendia.
- Recruiting
- Registry status
- 30,000
- Enrollment target
- 20
- Study locations
NCT03053193 is a study of Breast Cancer that is actively recruiting participants, run by Agendia. The registered enrollment target is 30,000 participants, above the 2,779-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (980% higher). The trial reports 20 study locations across 8 states.
The verdict
NCT03053193, a study of Breast Cancer, is actively recruiting participants, sponsored by Agendia.
- RECRUITING
- Registry status
- 30,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
The FLEX Registry will be implemented to operate as a large-scale, population based, prospective registry. All patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing on a primary breast tumor are eligible for entry into the FLEX Registry, which is intended to enable additional study arms at low incremental effort and cost. FLEX Registry will utilize an adaptive design, where additional targeted substudies and arms can be added after the initial study is opened.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST MammaPrint, BluePrint, and Full-Genome Testing
Study Locations (20)
California
- Adventist Health - Bakersfield - Bakersfield
- Comprehensive Cancer Center at Desert Regional Medical Center - Palm Springs
- North Valley Breast Clinic - Redding
- UCSF Breast Care Center - San Francisco
- Valley Breast Care - Van Nuys
Colorado
- Rocky Mountain Cancer Centers - Aurora
- University of Colorado Cancer Center - Aurora
- Comprehensive Breast Care of Denver - Denver
- Rocky Mountain Cancer Center - Lakewood - Lakewood
- Vail Health - Shaw Cancer Center - Vail
Florida
- Breast Specialists of South Florida - Atlantis
- JFK Medical Center - Atlantis
- Boca Raton Regional Hospital - Boca Raton
- Morton Plant Hospital - Clearwater
Arizona
- Arizona Oncology Associates, PC - Phoenix
- Arizona Oncology Associates, PC - HOPE - Tucson
Alabama
- CHS Grandview - Birmingham
Alaska
- Providence Alaska Medical Center - Anchorage
Connecticut
- St. Mary's Hospital - Waterbury
Delaware
- Medical Oncology and Hematology Consultants - Newark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30,000 participants |
| Start Date | 2017-04-28 |
| Est. Completion | 2037-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03053193
The ClinicalTrials.gov registry entry for NCT03053193 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 30,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 2,779-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (980% higher). The listed sponsor is Agendia, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which MammaPrint, BluePrint, and Full-Genome Testing is the first listed.
NCT03053193 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Colorado, Florida.
Frequently Asked Questions
What is clinical trial NCT03053193 about?
NCT03053193 is a clinical study titled "MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles". The FLEX Registry will be implemented to operate as a large-scale, population based, prospective registry. All patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing on a primary breast tumor are eligible for entry into the FLEX Registry, which is intended to enable...
What is the current status of trial NCT03053193?
This trial is currently recruiting. The enrollment target is 30,000 participants. The study started on 2017-04-28. Estimated completion is 2037-12.
What conditions does trial NCT03053193 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT03053193?
The interventions under investigation include: MammaPrint, BluePrint, and Full-Genome Testing (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03053193?
This trial is sponsored by Agendia, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03053193 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Surviving Daily Life
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.